Kaposi sarcoma
Meaning of kaposi sarcoma: For the purposes of this Statement of Principles, Kaposi sarcoma: (a) means a multicentric vascular neoplasm arising from endothelial cells and characterised by the proliferation of spindle cells, formation of new blood vessels and inflammation; and (b) excludes soft tissue sarcoma.
Reasonable Hypothesis (RH) — Statement of Principles No. 1 of 2020
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting Kaposi sarcoma or death from Kaposi sarcoma with the circumstances of a person's relevant service:
- (1)having infection with human herpesvirus type 8 before the clinical onset of Kaposi sarcoma;
- (2)having infection with human immunodeficiency virus before the clinical onset of Kaposi sarcoma;
- (3)having non-Hodgkin lymphoma or chronic lymphocytic leukaemia/small lymphocytic lymphoma before the clinical onset of Kaposi sarcoma;
- (4)having chronic renal failure at least six months before the clinical onset of Kaposi sarcoma;
Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
- (5)having an autoimmune disease from the specified list of autoimmune diseases at least six months before the clinical onset of Kaposi sarcoma;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
- (6)having diabetes mellitus for at least six months before the clinical onset of Kaposi sarcoma;
- (7)having lymphoedema involving the affected site at least five years before the clinical onset of Kaposi sarcoma;
- (8)undergoing solid organ, stem cell or bone marrow transplantation before the clinical onset of Kaposi sarcoma;
- (9)being treated with an immunosuppressive drug: (a) for a continuous period of at least three months before the clinical onset of Kaposi sarcoma; and (b) where that exposure has ceased, the clinical onset of Kaposi sarcoma has occurred within ten years of cessation;
Note: immunosuppressive drug is defined in the Schedule 1 - Dictionary.
- (10)being treated with an angiotensin converting enzyme inhibitor: (a) for at least three months before the clinical onset of Kaposi sarcoma; and (b) where that exposure has ceased, the clinical onset of Kaposi sarcoma has occurred within ten years of cessation;
- (11)inability to obtain appropriate clinical management for Kaposi sarcoma;
Aggravation-only factors: the factors in subsection 9(11) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.








